Scancell builds momentum with third deal for AvidiMab™ platform
This marks the third collaborative agreement for the developer of novel immunotherapies for the treatment of cancer and follows two prior deals inked in September 2019 and December 2019, respectively.
Under the deal, research will include an evaluation of Scancell's pipeline of anti-TaG mAbs to target tumour cells which have been engineered using the Company's AvidiMab™ technology.
Shares in Scancell Holdings reacted positively and were trading 14.40% higher at 7.15p on Monday morning.
AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies -- this means inducing monoclonal antibodies (mAbs) with direct tumour cell killing properties to target TaGs, tumour-associated glycans.
“This continued momentum with AvidiMab™ and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform,” said Dr Cliff Holloway, Chief Executive of Scancell.
The group highlighted the platform's ‘broad potential’ to optimise any therapeutic monoclonal antibody including those being developed for autoimmune diseases as well as cancer.
The company views the collaboration as significant for extracting future value via the potential of this third platform, added Holloway.
Separately, Scancell is currently developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Follow News & Updates from Scancell Holdings here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.